MAPLE GROVE, Minn., Dec. 1, 2025 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne ...

Upsher-Smith, a subsidiary of Bora Pharmaceuticals, is offering Kymbee (deflazacort) oral suspension, 22.75 mg/ml. The medication is indicated for the treatment of Duchenne muscular dystrophy in ...

Upsher-Smith Laboratories, LLC (Upsher-Smith), a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX) today ...

NORTHBROOK, Ill.--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC (Marathon), a U.S. research-based biopharmaceutical company focused solely on the development of new treatments for rare diseases, ...

Kymbee is indicated for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older. “At Upsher-Smith, we recognize the challenges associated with accessing certain medications ...

Deflazacort (Dacort) is a glucocorticoid, prescribed for anti-inflammatory conditions, and used as an immunosuppressant. It is a prodrug. The information provided on this page is intended to serve as ...

Both low and high doses of deflazacort (Marathon Pharmaceuticals) are effective in increasing muscle strength in children and adolescents with Duchenne muscular dystrophy (DMD), suggests results of a ...

Zydus Lifesciences share price extended the gains on second day, rising 1 percent in the early trade on April 15 following United States Food and Drug Administration (USFDA) approval for Jaythari ...

Zydus Lifesciences Limited on Monday said it received final approval from the health regulator of the United States for Deflazacort oral suspension used for treating a severe form of muscular ...

Deflazacort (Deza) is a glucocorticoid, prescribed for anti-inflammatory conditions, and used as an immunosuppressant. It is a prodrug. The information provided on this page is intended to serve as a ...